Zepbound self-pay price
Brand-name tirzepatide, cash price. The dose ladder, the conditions attached to it, and what the year actually models to.
As of August 31, 2026:
Zepbound self-pay through LillyDirect vials runs $299 per month at 2.5 mg, $399 at 5 mg and $449 at 7.5–15 mg under Lilly’s Self Pay Journey conditions (verified August 25, 2026, grade B; regular prices of $499–$699 apply if the refill-window conditions are missed, and the stated terms run through December 31, 2026). Modeled on the labeled titration, a self-pay year is about $4,938 before any consultation fees. Through a telehealth membership such as Ro the same Lilly pricing applies plus the membership, modeled at about $4,977 for the year. For comparison, the cheapest first-party-verified compounded tirzepatide year is $1,500 (Trimi, grade B) — but Zepbound is an FDA-approved product and compounded tirzepatide is not; they are different regulatory categories, not interchangeable versions of one product.
| Provider | Plan | Advertised /mo | All-in /mo, maintenance dose | 12-month all-in | Dose pricing | Membership | Included | Grade | Verified | Change | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LillyDirect brandbrand-name vial | month-to-month | $299 | $449 | $4,938 | rises with dose | none | care: paid; shipping included | B | — | zepbound.lilly.com | |
| Ro brandbrand-name pen | month-to-month | $299 | $449 | $4,977 | rises with dose | not published | care and shipping | B | — | ro.co |
Grades: A = price and terms verified on the provider’s page; B = price verified, some terms unpublished; C = introductory price only; D = third-party report, not verified by us; U = no public price. Grade D rows are shown for completeness and are never counted in verified statistics. Full definitions.
Mounjaro
Mounjaro is the same molecule (tirzepatide) approved for type 2 diabetes. The dataset contains no verified cash-pay Mounjaro program — Lilly’s self-pay route is Zepbound vials — so no Mounjaro price is shown rather than an invented one; with insurance, coverage and copays are plan-specific.
Zepbound versus compounded tirzepatide on price
The verified compounded floor is $125 per month (Trimi, 12-month plan) against $299–$449 by dose for Zepbound vials. The regulatory difference is not a footnote: Zepbound is FDA-approved; compounded tirzepatide is not FDA-approved or FDA-reviewed. Full comparison: compounded vs Zepbound cost.
Questions this page answers
How much is Zepbound without insurance?
Zepbound self-pay through LillyDirect vials runs $299 per month at 2.5 mg, $399 at 5 mg and $449 at 7.5–15 mg under Lilly’s Self Pay Journey conditions (verified August 25, 2026, grade B; regular prices of $499–$699 apply if the refill-window conditions are missed, and the stated terms run through December 31, 2026). Modeled on the labeled titration, a self-pay year is about $4,938 before any consultation fees. Through a telehealth membership such as Ro the same Lilly pricing applies plus the membership, modeled at about $4,977 for the year. For comparison, the cheapest first-party-verified compounded tirzepatide year is $1,500 (Trimi, grade B) — but Zepbound is an FDA-approved product and compounded tirzepatide is not; they are different regulatory categories, not interchangeable versions of one product.
What happens if I miss the Self Pay Journey refill window?
Lilly’s stated regular self-pay prices of $499–$699 per month apply instead of $299–$449; the offer terms as verified run through December 31, 2026. The condition is printed on the row because it changes the price by up to $250 a month.